Cargando…
Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy
OBJECTIVES: This study aimed to describe the epidemiology and risk factors of cholelithiasis and nephrolithiasis among HIV-positive patients in the era of combination antiretroviral therapy. METHODS: We retrospectively reviewed the medical records of HIV-positive patients who underwent routine abdom...
Autores principales: | Lin, Kuan-Yin, Liao, Sih-Han, Liu, Wen-Chun, Cheng, Aristine, Lin, Shu-Wen, Chang, Sui-Yuan, Tsai, Mao-Song, Kuo, Ching-Hua, Wu, Mon-Ro, Wang, Hsiu-Po, Hung, Chien-Ching, Chang, Shan-Chwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567270/ https://www.ncbi.nlm.nih.gov/pubmed/26360703 http://dx.doi.org/10.1371/journal.pone.0137660 |
Ejemplares similares
-
Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy
por: Cheng, Aristine, et al.
Publicado: (2016) -
Risk of elevation of serum creatine kinase among HIV-positive individuals receiving dolutegravir-based combination antiretroviral therapy
por: Chen, Guan-Jhou, et al.
Publicado: (2019) -
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy
por: Huang, Sung-Hsi, et al.
Publicado: (2017) -
Therapeutic Drug Monitoring and Pharmacogenetic Study of HIV-Infected Ethnic Chinese Receiving Efavirenz-Containing Antiretroviral Therapy with or without Rifampicin-Based Anti-Tuberculous Therapy
por: Lee, Kuan-Yeh, et al.
Publicado: (2014) -
Immune Reconstitution Inflammatory Syndrome in People Living with HIV Who Presented with Interstitial Pneumonitis: an Emerging Challenge in the Era of Rapid Initiation of Antiretroviral Therapy
por: Chen, Kai-Hsiang, et al.
Publicado: (2023)